“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

James D'Arecca Biography and Net Worth

CFO of TherapeuticsMD

James C. D'Arecca serves as Chief Financial Officer of the Company. He served as Senior Vice President and Chief Accounting Officer of Allergan plc (formerly known as Actavis plc) from August 2013 until its merger with AbbVie Inc. in May 2020. Mr. D’Arecca was a key member of the finance team through Allergan’s journey from a generics manufacturer (Watson/Actavis) to a leading global pharmaceutical company. Mr. D’Arecca joined Actavis from Bausch & Lomb, where he served as its Chief Accounting Officer. Prior to Bausch & Lomb, Mr. D’Arecca served in various roles of increasing responsibility at Merck & Co. Inc. and Schering-Plough in finance and business development. He also spent 13 years with PricewaterhouseCoopers, with an industry focus on pharmaceuticals, medical devices, and consumer products. Mr. D’Arecca holds an M.B.A. from Columbia University and a B.S. in accounting from Rutgers University. He is a Certified Public Accountant.

How do I contact James D'Arecca?: The corporate mailing address for Mr. D'Arecca and other TherapeuticsMD executives is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. TherapeuticsMD can also be reached via phone at (561) 961-1900 and via email at [email protected]. Learn More on James D'Arecca's contact information.
Has James D'Arecca been buying or selling shares of TherapeuticsMD?: James D'Arecca has not been actively trading shares of TherapeuticsMD during the last quarter. Most recently, James Darecca sold 93,337 shares of the business's stock in a transaction on Thursday, August 12th. The shares were sold at an average price of $0.87, for a transaction totalling $81,203.19. Learn More on James D'Arecca's trading history.
Who are TherapeuticsMD's active insiders?: TherapeuticsMD's insider roster includes Paul Bisaro (Director), Edward Borkowski (EVP), Cooper Collins (Director), James D'Arecca (CFO), Michael Donegan (CAO), Robert Finizio (CEO), Tommy Thompson (Director), and Marlan Walker (General Counsel). Learn More on TherapeuticsMD's active insiders.
Are insiders buying or selling shares of TherapeuticsMD?: In the last twelve months, TherapeuticsMD insiders bought shares 1 times. They purchased a total of 1,200 shares worth more than $2,040.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 14,500 shares worth more than $33,495.00. The most recent insider tranaction occured on August, 21st when Director Cooper C Collins bought 1,200 shares worth more than $2,040.00. Insiders at TherapeuticsMD own 2.3% of the company. Learn More about insider trades at TherapeuticsMD.
Information on this page was last updated on 8/21/2024.

James D'Arecca Insider Trading History at TherapeuticsMD

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/12/2021	Sell	93,337	$0.87	$81,203.19

James D'Arecca Buying and Selling Activity at TherapeuticsMD

TherapeuticsMD Company Overview

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Today's Range

Now: $1.41

$1.40

$1.48

50 Day Range

MA: $1.62

$1.46

$1.79

2 Week Range

Now: $1.41

$1.40

$3.07

Volume

18,517 shs

Average Volume

17,414 shs

Market Capitalization

$16.26 million

P/E Ratio

N/A

Dividend Yield